Medical Device FDA Consent Decrees: The Order That Stops the Plant

A medical device FDA consent decree is a court order that can stop manufacturing and distribution until the company makes required corrections and the Food and Drug Administration authorizes a restart. It can reach the complaint files, the production line and the executives responsible for both. For a quality or regulatory employee, the important question is what happened between the day someone found the problem and the day management declared it fixed. That history can become the operating terms of the business.

These orders can require independent experts, restrict shipments and preserve supplies patients still need. A whistleblower case under the False Claims Act follows the government payment: what the manufacturer knew, what reached the healthcare provider and what the provider billed.

What Does a Medical Device FDA Consent Decree Control?

An FDA consent decree can put the company’s ability to make and ship devices under continuing court supervision. The named facilities and products define its reach. Required corrections, outside review and the agency’s written authorization determine when ordinary operations can resume.

Form FDA 483 records inspection observations, and a warning letter calls for correction. A consent decree gives the court power to enforce those corrections.

The scope can extend beyond the factory floor. The Philips Respironics order covers design, assembly, labeling, reworking and specification development. Its review reaches complaint handling, corrective and preventive action, supplier controls and decisions about whether device changes need a new premarket submission. A change described internally as a repair can therefore raise questions about manufacturing, design and authorization at once.

The people responsible for those decisions matter too. A decree can bind executives individually and require the business to bring a replacement executive under the order when responsibilities change. Moving work or changing a company’s name can also leave obligations attached to the operation. The order reaches the decisions that determine whether the correction actually happens.

Atrium and the Corrections That Kept Being Promised

Atrium Medical’s device business included surgical mesh, chest drains, vascular grafts and stent systems. Its government complaint, filed in 2015, alleged recurring failures in process validation, corrective action and finished-device acceptance at its Hudson, New Hampshire facility. It also alleged failures to report information suggesting a device may have caused or contributed to death or serious injury.

The complaint described similar quality problems in earlier inspections and an inadequate response to the latest inspection. Its account of management’s response was blunt:

That repetition is the point. The government’s complaint put the promised corrections beside the recurring findings. For someone inside a plant, the useful history includes what the response letter promised, what changed in production and what the next inspection found.

The resulting decree shut the Hudson plant subject to a medically necessary supply exception. The enforcement reached quality systems and device reporting. It also reached management: the government named the chief executive responsible for manufacturing and quality operations and the chief quality and regulatory officer. The complaint connected their authority to the systems the government said had failed.

Philips Had Separate Orders for Separate Device Businesses

Philips’ sleep-and-respiratory decree followed recalls involving the sound-abatement foam in its devices. The government alleged failures in manufacturing controls and in reporting required device information. Philips also had a separate decree for its defibrillator business. The 2017 defibrillator consent decree was entered in Massachusetts. The 2024 Respironics decree expressly leaves devices already governed by the earlier order under that order.

That separation matters inside a large manufacturer. The product, facility and activity covered by a decree determine which restrictions apply. The later order also controls transfers of covered manufacturing operations to affiliated businesses, requiring the receiving owner to become a party for those operations.

Patient Remedies Became a Condition of Restart

The Respironics decree makes completion of repair, rework, replacement and refund activities under its Recall Remediation Plan a condition of restarting ordinary operations at the covered facilities. The plan concerns recalls Philips initiated on June 14, 2021. The order’s definition of rework includes removing the original sound-abatement foam and, where applicable, replacing it with new foam.

The obligation reaches back to devices already distributed. Before ordinary manufacturing and distribution can resume, the company must meet the plan’s recall-effectiveness targets as well as the manufacturing and reporting requirements. Patient remediation sits beside factory compliance in the restart conditions.

The order also separates different kinds of expert work. A quality-system expert reviews the facilities and operating controls. A testing expert evaluates the new foam, including whether it will remain stable through the device’s labeled service life and address the original risks without introducing new ones. A design expert evaluates the replacement and reworked devices, their risk analysis and their validation.

Rework has its own quality review, including supplier controls for contractors performing manufacturing operations. This matters because replacing a component creates another manufacturing process to assess. The order requires evidence about both the proposed fix and the way that fix is performed.

The Food and Drug Administration can inspect the operations before authorizing restart. The company pays for the required expert work and FDA’s oversight costs. A favorable expert certification is part of that process. The agency’s written notification controls the restart. Silence does not count as permission.

Keeping Necessary Devices Available

The decree permits continued production and distribution of devices the Food and Drug Administration designates medically necessary. The agency controls additions to and removals from that list. It also preserves specified activities such as servicing devices already with customers and supplying certain consumables, accessories and replacement parts.

The exception has a financial consequence too. For medically necessary devices sold solely under that exception before the agency’s restart notification, Philips must pay the Treasury a share of net revenue. The decree sets the share at 10% through the end of 2024, 12% during 2025 and 25% thereafter while the condition applies. An independent financial auditor determines the amounts.

Oversight Continues After Restart

At the covered Respironics facilities, independent audits continue for five years after restart. The reports go to both the Food and Drug Administration and the company. The auditor must assess whether earlier corrections worked, and adverse findings can extend or restart the audit cycle.

The decree also gives the Food and Drug Administration standing authority to order corrective action in writing, including a shutdown. That can include stopping manufacturing, distribution or servicing, or requiring repair, replacement or refunds. Company reports, expert findings, inspection results and other information can trigger that authority.

The management obligation continues as well. When an individual defendant leaves, the company must designate a person with equivalent responsibilities for substitution by the court. The order ties each person’s obligations to that person’s authority, responsibilities and conduct. Responsibility follows the job through the substitution process.

Missed Corrections Carry Daily Payments

For missed corrective actions at other sleep-and-respiratory facilities, the Respironics decree requires payments of $10,000 per action per business day, capped at $10 million in a calendar year. The daily payments continue until the action satisfies the Food and Drug Administration.

Paying those amounts does not purchase permission to keep violating the order. The court retains power to enforce compliance.

Medtronic SynchroMed and the Evidence Behind a Correction

Medtronic’s SynchroMed II implantable infusion pumps were the focus of a 2015 government injunction complaint. Medtronic and the FDA resolved it with a consent decree. In a physician notice filed in the case on April 28, 2015, Medtronic said the decree limited manufacture and distribution of the pumps, except for replacement and medically necessary new patients, until an independent expert certified its quality system to the FDA’s satisfaction. The government alleged inadequate design validation, risk analysis, control of design changes and corrective-action procedures. It described repeated inspections and promises of correction, then alleged that the company’s responses failed to provide adequate evidence that the problems had been corrected.

The requested order would stop manufacturing and distribution of the pumps until the operation met the quality requirements in a manner the Food and Drug Administration found acceptable. The complaint named the chief executive and the head of the neuromodulation business, describing their authority over product development, compliance and other functions.

For a device engineer, the alleged problem is concrete. Identifying an action, implementing it and verifying that it works are distinct parts of a correction. The complaint challenged the procedures for verifying effectiveness and ensuring that a correction did not adversely affect the finished device.

The Other Device Orders Reach Different Problems

Pharmaceutical Innovations and the Executive Who Took Over

Pharmaceutical Innovations’ 2016 consent decree shows how an order can follow operational responsibility. A new president and chief executive took over while the case was underway. The decree recorded that he had no involvement in the company’s operations before taking that position, but he consented to become a defendant as the person then most responsible for operations. The earlier individual defendant was dismissed.

The practical point is who can make the company comply. A change at the top became a change in the person bound by the decree. The Philips substitution provisions address that same continuity of responsibility expressly.

In the QLasers matter, the government obtained an order against 2035 Inc. and the individual operating under the 2035 PMA and QLasers PMA business names after trial in 2015. The order’s payment terms were $10,000 per day plus $10,000 per violation.

Shelhigh and the Devices Under Seizure

Shelhigh’s 2007 consent order concerned seized devices and reconditioning. The order controlled the seized goods. The Philips plant order reaches ongoing manufacturing and distribution as well.

What Quality and Regulatory Employees Can See

The internal evidence starts with how a company receives a complaint, investigates it and decides what to report. Manufacturers receive serious-injury reports from user facilities and malfunction reports from importers. They make the reporting judgment about whether a malfunction would be likely to cause death or serious injury if it recurred.

That judgment depends on more than the initial complaint. Device testing can supply information the manufacturer is responsible for evaluating. Trend analysis can reveal the need for corrective action. The Philips decree reaches these connections directly, requiring review of accurate complaint files, reporting procedures, failure investigations and information sent to management.

Reporting exemptions also affect what appears publicly. The Food and Drug Administration’s former Alternative Summary Reporting program kept its reports out of public view before 2019. Voluntary Malfunction Summary Reporting makes its summaries available in the public MAUDE database. The reporting route and period matter when comparing an internal complaint history with the public record.

The useful insider account explains how the company reached its decision. Which test result informed the reporting assessment? Which recurring failure reached management? What evidence supported closing the corrective action? Those are the business decisions the decrees repeatedly bring under outside review.

How a Device Failure Connects to a Whistleblower Case

A manufacturer can face a whistleblower case over knowingly selling defective devices that cause false government claims. In the Exactech knee-implant settlement, the government alleged that the company kept selling components it knew failed prematurely. Its theory was that those devices were not reasonable and necessary for treatment, making the claims for them false. Patients received the implants, and public health care programs paid for them.

For a medical device fraud case, we connect the quality and reporting evidence to that transaction: the product used, what the manufacturer knew, the information reaching the provider and the government payment at issue. Philips’ decree leaves the government free to pursue separate False Claims Act claims.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We build the case around the connection between what happened inside the device business and the claims it caused.

How Does Reimbursement Work for Medical Devices?

Most implanted devices sit inside the hospital’s payment for a procedure or stay. A device code or charge can appear on the bill while the implant’s cost remains packaged into that payment. The manufacturer, the clinician selecting the device and the institution submitting the claim occupy different parts of the transaction. FDA marketing authorization, Medicare coverage and the payment method are separate decisions. The hospital’s purchase of a device and Medicare’s payment for the procedure therefore need to be traced separately.

You Know What Happened After the Inspection

If you worked on device complaints, testing or corrective actions and know what management left unresolved, speak with our medical device whistleblower experts. We build the case strategy around your knowledge of the product and bring in medical device whistleblower lawyers who understand manufacturing evidence and government payment. We stay beside you through the whole case, working to build your strongest medical device whistleblower case.